Jaclyn Bjorklund of Louisiana accuses Novo Nordisk, the maker of Ozempic, and Eli Lilly, which makes Mounjaro, another Type 2 diabetes treatment being used off-label for weight loss, of failing to warn or adequately warn of all the possible adverse side effects from using the medications, including the risk of gastroparesis, also known as paralyzed stomach. Bjorklund, 44, was diagnosed with Type 2 diabetes in 2017 and used Ozempic for more than one year, then stopped and switched to Mounjaro in July 2023 with both drugs prescribed by her doctors to control her blood sugar, according to court papers
These two medications work through complementary mechanisms with no major drug interactions, making the combination both safe and effective for most patients
Chronic inflammation can disrupt hormone signaling, including GLP-1 secretion
While we do look at BMI, we do not have a set BMI limit to qualify for our medical weight loss program
When calorie intake declines whether through semaglutide , tirzepatide , or other means the body prioritizes energy conservation